Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310009, China.
Eur Cytokine Netw. 2021 Dec 1;32(4):73-82. doi: 10.1684/ecn.2021.0472.
Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, with multifactorial etiologies has led to a global health-associated burden in many countries. Substantial efforts are devoted to understand the pathogenesis, behavioral and environmental triggers, which may be specifically valuable for the treatment of IBD. The specific pathogenesis underlying IBD is as yet incompletely understood. The use of anti-cytokine therapy and small molecule agents targeting the immune system is thought to restore the body's intestinal barrier function and relieve inflammation with manageable adverse effects. In this review, we report recent advances in anti-cytokine therapy and treatment with small molecule agents for the management of IBD.
炎症性肠病（IBD），包括克罗恩病和溃疡性结肠炎，具有多种病因，在许多国家导致了与健康相关的负担。人们投入了大量的努力来了解发病机制、行为和环境触发因素，这对于治疗 IBD 可能具有特别的价值。IBD 的具体发病机制尚未完全了解。使用抗细胞因子疗法和针对免疫系统的小分子药物被认为可以恢复机体的肠道屏障功能并缓解炎症，同时不良反应可控制。在这篇综述中，我们报告了抗细胞因子疗法和小分子药物治疗 IBD 的最新进展。
